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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Ecuadorian Spanish 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 23 JIA patients (17.4% systemic, 17.4% RF negative poly-arthritis, 17.4% 
RF positive poly-arthritis, and 47.8% other categories) and 23 healthy children were enrolled in the paediatric centre of 
Guayaquil. The JAMAR components discriminated well healthy subjects from JIA patients. Notably, there is no significant 
difference between the healthy subjects and their affected peers in the school-related problems variable. All JAMAR com-
ponents revealed good psychometric performances. In conclusion, the Ecuadorian Spanish version of the JAMAR is a valid 
tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Ecuadorian Spanish parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
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parent/patient reported outcomes in JIA, including overall 
well-being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance, and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Ecuadorian Spanish language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from April 2016 to 
January 2017. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 3 
components: PF-lower limbs (PF-LL), PF-hand and 
wrist (PF-HW), and PF-upper segment (PF-US) each 
scoring from 0 to 15 [7]. Higher scores indicate higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) sub-scales (5 
items each), and a total score. The four-point Lik-
ert response, referring to the prior month, is ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2), and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data, and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
item-scale correlations (Pearson r: all items within a scale 
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should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR sub-scales with 
the 6 JIA core-set variables, with the addition of the par-
ent assessment of disease activity and pain by the Spear-
man’s correlation coefficients (r) [17] and the discriminant 
validity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18]. Quantitative data were reported as medians with first 
and third quartiles and categorical data as absolute fre-
quencies and percentages.
The complete Ecuadorian.
Spanish parent and patient versions of the JAMAR are 
available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Ecuadorian Spanish JAMAR was cross-culturally 
adapted from the Argentinian Spanish version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range: 90–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range: 90–100%). 
Both versions of the JAMAR were unmodified after the 
probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 23 JIA patients and 23 healthy children (total of 
46 subjects) were enrolled at the paediatric rheumatology 
centre of Guayaquil.
In the 23 JIA subjects, the JIA categories were 17.4% 
with systemic arthritis, 4.3% with oligoarthritis, 17.4% 
with RF negative poly-arthritis, 17.4% with RF positive 
poly-arthritis, 8.7% with enthesitis-related arthritis, and 
34.8% with undifferentiated arthritis. Notably, none of the 
enrolled JIA patients is affected with psoriatic arthritis 
(Table 1).
All the 46 subjects had the parent version of the JAMAR 
completed by a parent (23 from parents of JIA patients and 
23 from parents of healthy children). The JAMAR was com-
pleted by 41/46 (89.1%) mothers and 5/46 (10.9%) fathers. 
The child version of the JAMAR was completed by all the 
46 children age 6 or older. In addition, patients younger than 
7 years, capable to assess their personal condition and able 
to read and write, were asked to fill in the patient version of 
the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (first–third quartiles)] obtained for the PF, 
the PhH, the PsH sub-scales, and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients. Notably, there is no sig-
nificant difference between the healthy subjects and their 
affected peers in the school-related problems.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. A 
reduced number of response choices were used for all the 
different HRQoL items (with the exception of item 3), and 
for the all the PF items, except for PF items 1, 3, 4, and 5.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items (data 
not shown). The median number of items marked as not 
applicable was 0% (0–0%) for the PF and for the HRQoL.
Floor and ceiling effect
The median floor effect was 87% (78.3–91.3%) for the PF 
items, 60.9% (56.5–60.9%) for the HRQoL-PhH items, and 
78.3% (69.6–78.3%) for the HRQoL-PsH items. The median 
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Table 1  Descriptive statistics (medians, first and third quartiles or absolute frequencies and %) for the 23 JIA patients
Data related to the JAMAR refers to the 23 JIA patients and to the 23 healthy subjects for whom the questionnaire has been completed by the 
parents. p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
Systemic Oligoarthritis RF- poly-
arthritis
RF + poly-
arthritis
Enthesitis-
related arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 4 N = 1 N = 4 N = 4 N = 2 N = 8 N = 23 N = 23
Female 3 (75%) 1 (100%) 2 (50%) 4 (100%) 0 (0%) 6 (75%) 16 (69.6%) 10 (43.5%)
Age at visit 11.5 (8.6–14) 9.2 (9.2–9.2) 12 (8.8–14.6) 13 (11.3–14.5) 15.5 (14.6–
16.4)
14.3 (11.7–
15.6)
14.3 (10.9–
14.7)
11.6 (9.9–14.3)
Age at onset 4.9 (4.5–10.5) 8.5 (8.5–8.5) 3.1 (2.2–8.8) 10.5 
(9.7–12.1)
13.5 (11.9–15) 11 (9.9–12.5) 10.6 (5–12.7)
Disease duration 4.2 (1-6.6) 0.7 (0.7–0.7) 5.7 (3.3–9.2) 1.5 (1–3) 2 (1.3–2.7) 1.5 (0.8–4.7) 1.8 (1–5.2)
ESR 18 (11.5–22.5) 28 (28–28) 26 (20–36) 15 (10–26) 7 (7–7) 22 (9–29) 22 (9–28)
MD VAS 
(0–10 cm)
2.5 (1-3.5) 1.5 (1.5–1.5) 0 (0-1.5) 1.5 (0.8–2.3) 0 (0–0) 0 (0-1.8) 0 (0–2)
No. swollen 
joints
0.5 (0–2) 0 (0–0) 0 (0–1) 0 (0-0.5) 0 (0–0) 0 (0–1) 0 (0–1)
No. joints with 
pain
0.5 (0-1.5) 1 (1–1) 0 (0–1) 1 (0.5–1) 0 (0–0) 0.5 (0–2) 0 (0–1)
No. joints with 
LOM
0 (0-4.5) 0 (0–0) 2.5 (0-6.5) 1 (0.5–1.5) 0 (0–0) 0.5 (0-2.5) 0 (0–2)
No. active joints 0.5 (0–2) 0 (0–0) 0 (0–1) 0.5 (0–1) 0 (0–0) 1 (0–2) 0 (0–1)
Active systemic 
features
3 (75%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (13%)*
ANA status 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Uveitis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PF Total Score 0.5 (0–8) 1 (1–1) 5.5 (2–7.5) 0 (0–0) 0 (0–0) 0 (0–12.5) 0 (0–7) 0 (0–1)*
Pain VAS 2.3 (0.5–4.8) 2 (2–2) 3.5 (1.3–7) 2.5 (0.5–4.5) 0.8 (0–1.5) 0.3 (0–1.3) 1 (0–4) 0 (0–0)*
Disease Activity 
VAS
1.8 (0-5.3) 2 (2–2) 2.3 (0.5–4) 1.8 (0.5–3.3) 0 (0–0) 0.3 (0–1.5) 0.5 (0–3.5)
Well-being VAS 2 (0.3–6.3) 0 (0–0) 2.5 (1–4) 1.5 (0.5–3.3) 0 (0–0) 0 (0–2) 1 (0–3.5)
HRQoL-PhH 3 (1.5–5.5) 2 (2–2) 4 (3–4.5) 2.5 (1–4.5) 0 (0–0) 0.5 (0–5) 2 (0–5) 0 (0–1)*
HRQoL-PsH 1 (0.5-3) 3 (3–3) 2.5 (1–3.5) 0 (0–1.5) 0 (0–0) 0 (0–3) 0 (0–3) 0 (0–2)*
HRQoL Total 
Score
4 (2-8.5) 5 (5–5) 7 (4–8) 2.5 (1–6) 0 (0–0) 0.5 (0–8) 3 (0–8) 0 (0–3)*
Pain/swell in > 1 
joint
2 (50%) 1 (100%) 3 (75%) 3 (75%) 0 (0%) 4 (50%) 13 (56.5%) 1 (4.3%)**
Morning stiff-
ness > 15 min
0 (0%) 0 (0%) 0 (0%) 2 (50%) 0 (0%) 1 (12.5%) 3 (13%)
Subjective 
remission
2 (50%) 1 (100%) 2 (50%) 2 (50%) 0 (0%) 2 (25%) 9 (39.1%)
In treatment 4 (100%) 1 (100%) 4 (100%) 4 (100%) 2 (100%) 8 (100%) 23 (100%)
Reporting side 
effects
2 (50%) 1 (100%) 2 (50%) 0 (0%) 2 (100%) 2 (25%) 9 (39.1%)
Taking medica-
tion regularly
4 (100%) 1 (100%) 3 (75%) 4 (100%) 2 (100%) 8 (100%) 22 (95.7%)
With problems 
attending 
school
1 (33.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (7.1%) 0 (0%)
Satisfied with 
disease out-
come
3 (75%) 1 (100%) 2 (50%) 4 (100%) 2 (100%) 6 (75%) 18 (78.3%)
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ceiling effect was 0% (0–8.7%) for the PF items, 0% (0–0%) 
for the HRQoL-PhH items, and 0% (0–0%) for the HRQoL-
PsH items. The median floor effect was 30.4% for the pain 
VAS, 39.1% for the disease activity VAS and 43.5% for the 
well-being VAS. The median ceiling effect was 0% for the 
pain VAS, 0% for the disease activity VAS, and 0% for the 
well-being VAS.
Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 67% of the 
PF items, with the exception of items 8, 9, 13, 14, and 15 
and for 70% of the HRQoL items, with the exception of 
items 1, 2, and 6.
Table 2  Main psychometric characteristics between the parent and child versions of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 23 Child N = 23
Missing values (first–third quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 87.0% 91.3%
 HRQoL-PhH 60.9% 69.6%
 HRQoL-PsH 78.3% 73.9%
 Pain VAS 30.4% 30.4%
 Disease activity VAS 39.1% 34.8%
 Well-being VAS 43.5% 39.1%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL-PhH 0.0% 0.0%
 HRQoL-PsH 0.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item-scale correlation 67% for PF, 70% for HRQoL 87% for PF, 70% for HRQoL
Items with item-scale correlation ≥ 0.4 80% for PF, 70% for HRQoL 47% for PF,50% for HRQoL
Cronbach’s alpha
 PF-LL 0.98 0.96
 PF-HW 0.79 0.54
 PF-US 0.38 0.00
 HRQoL-PhH 0.74 0.63
 HRQoL-PsH 0.70 0.64
Items with item-scale correlation lower than the Cronbach alpha 87% for PF, 90% for HRQoL 80% for PF, 80% for HRQoL
Test–retest intra-class correlation
 PF total score 1.00 –
 HRQoL- PhH 0.89 –
 HRQoL- PsH 0.96 –
Spearman correlation with JIA core-set variables, median
 PF 0.4 0.4
 HRQoL-PhH 0.4 0.4
 HRQoL-PsH 0.3 0.2
 Pain VAS 0.2 0.4
 Disease activity VAS 0.4 0.2
 Well-being VAS 0.4 0.4
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Items internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 80% of items 
of the PF (except for items 13, 14, and 15) and 70% of items 
of the HRQoL (except for items 1, 8, and 10).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.98 for PF-LL, 0.79 for PF-HW, and 
0.38 for PF-US. Cronbach’s alpha was 0.74 for HRQoL-PhH 
and 0.70 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha, with 
the exception of the PF items 11 and 12 and of the HRQoL 
items 2 and 6 (data not shown).
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 7 days (range 7–7 days). The intra-class cor-
relation coefficients (ICC) for the PF total score showed 
an almost perfect reproducibility (ICC = 1.0). The ICC 
for the HRQoL-PhH and for the HRQoL-PsH showed an 
almost perfect reproducibility (ICC = 0.89 and ICC = 0.96, 
respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.2 to 0.5 
(median = 0.4). The PF total score best correlation was 
observed with the parent global assessment of well-being 
(r = 0.55, p = 0.006). For the HRQoL, the median correla-
tion of the PhH with the JIA core set of outcome variables 
ranged from 0.4 to 0.7 (median = 0.4) whereas for the PsH 
ranged from 0.2 to 0.6 (median = 0.3). The HRQoL-PhH 
and the HRQoL-PsH showed the best correlation with the 
parent global assessment of well-being (r = 0.92, p < 0.001 
and r = 0.76, p < 0.0001, respectively). The median correla-
tions between the pain VAS, the well-being VAS, and the 
disease activity VAS and the physician-centered and labora-
tory measures were 0.2.
(0.1–0.3), 0.4 (0.3–0.4), 0.4 (0.2–0.5), respectively.
Discussion
In this study, the Ecuadorian Spanish version of the JAMAR 
was cross-culturally adapted from the Argentinian Spanish 
version. According to the results of the validation analysis, 
the Ecuadorian Spanish parent and patient versions of the 
JAMAR possess satisfactory psychometric properties. The 
disease-specific components of the questionnaire discrimi-
nated well between patients with JIA and healthy controls. 
Notably, there was no significant difference between the 
healthy subjects and their affected peers in the school-related 
problem variable. This finding indicates that children with 
JIA adapt well to the consequences of JIA.
Psychometric performances were good for all domains 
of the JAMAR with some exceptions: 3 PF items (“Turn 
the head and look over the shoulders”, “Bend the head back 
and look at the ceiling” and “Bite into a sandwich or an 
apple”) and 3 HRQoL items (“Difficulty of taking care of 
him/herself”, “Having trouble getting along with other chil-
dren” and “Appeared to be dissatisfied with his/her physi-
cal appearance or abilities”) showed a lower item’s internal 
consistency. However, the overall internal consistency was 
at least acceptable for all the domains, with the exception of 
the PF-US Cronbach’s alpha that was poor.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters ranged from weak to moderate.
The results obtained for the parent version of the JAMAR 
are similar, although slightly poorer, to those obtained for 
the child version, which suggests that children are equally 
reliable proxy reporters of their disease and health status 
as their parents. However, we have to acknowledge that a 
limited sample of patients was recruited at the study Unit.
JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for 
intervention and follow-up in health care. In conclusion, 
the Ecuadorian Spanish version of the JAMAR was found 
to have satisfactory psychometric properties and it is, thus, 
a reliable and valid tool for the multidimensional assessment 
of children with JIA.
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